Heterocyclic antiviral compounds
    1.
    发明授权
    Heterocyclic antiviral compounds 失效
    杂环抗病毒化合物

    公开(公告)号:US07164019B2

    公开(公告)日:2007-01-16

    申请号:US11147851

    申请日:2005-06-08

    IPC分类号: C07D239/24

    CPC分类号: C07D487/04

    摘要: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

    摘要翻译: 趋化因子受体拮抗剂,特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物是可用于治疗或预防人类免疫缺陷病毒(HIV)感染或治疗AIDS的趋化因子CCR5受体的拮抗剂 或ARC。 本发明还提供了治疗与CCR5拮抗剂相关的疾病的方法。 本发明包括药物组合物和使用该化合物治疗这些疾病的方法。 本发明还包括制备式I化合物的方法。

    Heterocyclic antiviral compounds
    2.
    发明授权
    Heterocyclic antiviral compounds 失效
    杂环抗病毒化合物

    公开(公告)号:US07714018B2

    公开(公告)日:2010-05-11

    申请号:US11637423

    申请日:2006-12-11

    CPC分类号: C07D487/04

    摘要: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

    摘要翻译: 趋化因子受体拮抗剂,特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物是可用于治疗或预防人类免疫缺陷病毒(HIV)感染或治疗AIDS的趋化因子CCR5受体的拮抗剂 或ARC。 本发明还提供了用于治疗被CCR5拮抗剂缓解的疾病的方法。 本发明包括药物组合物和使用该化合物治疗这些疾病的方法。 本发明还包括制备式I化合物的方法。

    Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists
    3.
    发明授权
    Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists 失效
    八氢吡咯并[3,4-c]吡咯CCR5受体拮抗剂

    公开(公告)号:US07625905B2

    公开(公告)日:2009-12-01

    申请号:US11901498

    申请日:2007-09-18

    IPC分类号: A61K31/4545

    CPC分类号: C07D487/04

    摘要: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

    摘要翻译: 趋化因子受体拮抗剂,特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物,其中R 1 -R 3和Ar如本文所定义,是趋化因子CCR5受体的拮抗剂,其可用于治疗或预防人 免疫缺陷病毒(HIV)感染或治疗AIDS或ARC。 本发明还提供了用于治疗被CCR5拮抗剂缓解的疾病的方法。 本发明包括药物组合物和使用该化合物治疗这些疾病的方法。 本发明还包括制备式I化合物的方法。

    Heterocylic antiviral compounds
    4.
    发明申请
    Heterocylic antiviral compounds 失效
    异种抗病毒化合物

    公开(公告)号:US20080249087A1

    公开(公告)日:2008-10-09

    申请号:US12079746

    申请日:2008-03-28

    CPC分类号: C07D498/10

    摘要: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPD.

    摘要翻译: 本发明涉及式I的哌啶衍生物,其中R 1,R 2,R 3和R 4是 如本文所定义的,可用于治疗多种疾病,包括涉及CCR5受体调节的疾病。 本衍生物可能治疗或预防的疾病包括艾滋病病毒和遗传相关的逆转录病毒感染(以及由此获得的获得性免疫缺陷综合征,AIDS),类风湿关节炎,实体器官移植排斥(移植物抗宿主病),哮喘和COPD。

    Heterocylic antiviral compounds
    5.
    发明授权
    Heterocylic antiviral compounds 失效
    异种抗病毒化合物

    公开(公告)号:US07625891B2

    公开(公告)日:2009-12-01

    申请号:US12079746

    申请日:2008-03-28

    IPC分类号: C07D413/14 A61K31/537

    CPC分类号: C07D498/10

    摘要: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPD.

    摘要翻译: 本发明涉及式I的哌啶衍生物,其中R 1,R 2,R 3和R 4如本文所定义,可用于治疗各种疾病,包括涉及CCR5受体调节的疾病。 本衍生物可能治疗或预防的疾病包括艾滋病病毒和遗传相关的逆转录病毒感染(以及由此获得的获得性免疫缺陷综合征,AIDS),类风湿关节炎,实体器官移植排斥(移植物抗宿主病),哮喘和COPD。

    Heterocyclic antiviral compounds
    9.
    发明申请
    Heterocyclic antiviral compounds 审中-公开
    杂环抗病毒化合物

    公开(公告)号:US20090028818A1

    公开(公告)日:2009-01-29

    申请号:US12220485

    申请日:2008-07-24

    摘要: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.

    摘要翻译: 本发明涉及式I的哌啶衍生物,其中R 1,R 2,R 3和R 4如本文所定义,可用于治疗各种疾病,包括涉及CCR5受体调节的疾病。 可以由本发明衍生物治疗或预防的疾病包括HIV和遗传相关的逆转录病毒感染(和所得的获得性免疫缺陷综合征,AIDS),类风湿性关节炎,实体器官移植排斥(移植物抗宿主病),哮喘和COPR。